KR-20260062261-A - Novel lactic acid bacteria strain Leuconostoc mesenteroides DB1 isolated from Camellia japonica flower and anti-inflammatory composition using exosome thereof

Abstract

The novel Leuconostoc mesenteroides DB1 strain of the present invention is a strain isolated from camellia flowers and is deposited under accession number KACC 92611P, and its exosomes can exhibit excellent anti-inflammatory activity.

Inventors

• 지원재
• 김다솜

Assignees

• 대한민국(기후에너지환경부 국립생물자원관장)

Dates

Publication Date

20260507

Application Date

20241028

Claims (8)

1. Leuconostoc mesenteroides DB1 strain deposited under accession number KACC 92611P.
2. Exosomes derived from the strain of claim 1.
3. An anti-inflammatory composition containing the exosomes of claim 2 as an active ingredient.
4. An anti-inflammatory composition according to claim 3, wherein the exosomes are obtained by purifying a culture medium obtained by culturing the strain in MRS medium.
5. An anti-inflammatory composition according to claim 3, wherein the exosomes are obtained by purifying a culture medium obtained by shaking culture the strain in a liquid medium at 25 to 35°C for 15 to 20 hours.
6. A step of culturing the strain of claim 1 in a liquid medium to obtain a culture solution; and Step of purifying exosomes derived from the strain from the above culture medium A method for producing an anti-inflammatory substance including
7. A method for producing an anti-inflammatory substance, wherein the liquid medium in paragraph 6 is an MRS medium.
8. A method for producing an anti-inflammatory substance according to claim 6, wherein the culture is a shaking culture at 25 to 35°C for 15 to 20 hours.

Description

Novel lactic acid bacteria strain Leuconostoc mesenteroides DB1 isolated from Camellia japonica flower and anti-inflammatory composition using exosome thereof The present invention relates to a novel lactic acid bacteria strain, Leuconostoc mesenteroides DB1, isolated from camellia flowers, and an anti-inflammatory composition using the exosome thereof. More specifically, the present invention relates to a novel lactic acid bacteria strain isolated from camellia flowers, the exosome produced therefrom exhibiting excellent anti-inflammatory activity and thus being usable for preventing, treating, or improving inflammation, and to exosomes derived therefrom, and further relates to an anti-inflammatory composition utilizing the same that can provide excellent anti-inflammatory effects, and a method for efficiently producing anti-inflammatory substances. Active research is being conducted to identify and utilize commercially and/or industrially useful microorganisms among the numerous microorganisms in nature. Although various useful microorganisms have been discovered and utilized to date, it is still necessary to expand the pool of available microorganisms by newly discovering them; in particular, there is a need to identify microorganisms capable of exhibiting superior characteristics. Anti-inflammatory activity is attracting significant interest in the medical, functional cosmetics, and food industries. As it becomes clear that many diseases are associated with inflammatory responses, interest is growing in the production and/or inhibition of activity of various inflammatory mediators for the prevention and treatment of inflammatory diseases. Inflammation is an immune response of biological tissues to defend the body against trauma or tissue damage caused by physical or chemical stimuli, and is a series of biological processes carried out by various immune cells. Generally, the inflammatory response is induced by various pro-inflammatory mediators, including nitric oxide (NO), prostaglandins (PG), and pro-inflammatory cytokines such as TNF-α (tumor necrosis factor-α), IL-6 (interleukin-6), and IL-1β (interleukin-1β), which are secreted by various immune-related cells in damaged tissues. These mediators act as agents of various diseases by manifesting inflammatory symptoms such as pain, swelling, and fever. Macrophages, known as major inflammatory cells in the body, recognize lipopolysaccharide (LPS), an external membrane toxin of Gram-negative bacteria, through toll-like receptors (TLRs) expressed on their cell surfaces, thereby activating the signaling pathway of the intracellular transcription factor NF-κB (nuclear factor-κB). NF-κB, having moved into the nucleus of the macrophage, induces the expression of inflammation-related genes iNOS (inducible nitric oxide synthase) and COX-2 (cyclooxygenase-2), which in turn increases the production of inflammatory mediators such as NO and PGE2 (Prostaglandin E2). Among these, NO is a type of highly reactive radical that performs important physiological roles in the human body, such as signal transduction and immune responses through bacterial death, at low concentrations; however, it is known that when overexpressed, it induces inappropriate inflammation in the body, leading to genetic mutations and damage to tissues and nerves. Furthermore, it has been reported that various intractable diseases are caused by inducing the acute expression of COX-2, such as by increasing its catalytic activity and triggering signal transduction cascades, thereby increasing the production of PGE2. Considering that the excessive production of NO and PGE2, which are the causes of these inflammatory diseases, is mediated by inducible iNOS and COX-2, substances that inhibit the gene expression of iNOS and COX-2 can be seen as having high potential for use as materials to regulate inflammatory responses. The inventors sought to discover useful microbial resources from various natural samples, particularly new microbial resources capable of producing substances that exhibit excellent anti-inflammatory activity by effectively controlling inflammation-related activities as described above, or utilizing such substances for production. Figure 1 shows the 16S rRNA gene sequence of the Leuconostoc mesenteroides DB1 strain of the present invention. Figure 2 shows the Nanoparticle Tracking Analysis (NTA) results of exosomes purified from the DB1 strain of the present invention. Figure 3 shows the results of a cytotoxicity test of exosomes purified from the DB1 strain of the present invention. Figure 4 shows the experimental results of the nitric oxide (NO) production inhibitory activity of exosomes purified from the DB1 strain of the present invention. Figure 5 shows the experimental results of the PGE2 (Prostaglandin E2) production inhibitory activity of exosomes purified from the DB1 strain of the present invention. Figure 6 shows the experimental results of the COX-2 and iNOS protein expressio